Lyell Immunopharma has acquired exclusive global rights, outside of mainland China, Hong Kong, Macau, and Taiwan, to LYL273, a next-generation CAR T-cell product candidate targeting metastatic colorectal cancer. LYL273, which is currently in a U.S. Phase 1 clinical trial, has shown a 67% overall response rate and an 83% disease control rate at its highest dose, along with a manageable safety profile in patients with refractory metastatic colorectal cancer. Under the agreement, Lyell will make a $40 million upfront payment and issue 1.9 million shares of its common stock to ICT, the original developer. ICT is also eligible for additional milestone payments, further equity, and tiered royalties on future sales. Lyell expects the transaction to have a modest impact on 2025 operating expenses and projects cash reserves to fund operations into 2027.